Journal of Chinese Pharmaceutical Sciences ›› 2018, Vol. 27 ›› Issue (3): 143-158.DOI: 10.5246/jcps.2018.03.016

• Original articles •     Next Articles

Design, synthesis, and in vitro activity of methylisoxazole/isothiazole amides as BACE1 inhibitors

Peng Lv, Can Li, Yan Niu*, Hongyue Li, Tongliang Zhou, Fengrong Xu, Lei Liang, Chao Wang, Ping Xu*   

  1. Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
  • Received:2017-11-30 Revised:2018-02-03 Online:2018-03-31 Published:2018-02-28
  • Contact: Tel.: +86-010-82801558; +86-010-82802632, E-mail:;
  • Supported by:
    The National Natural Science Foundationof China (Grant No. 21002002) and the Beijing Natural Science Foundation (Grant No. 7162110).


Based on the structure of compound B51 (IC50 = 37.4 μM), which was discovered as hit in a previous virtual screen, a series of methylisoxazole/isothiazole amide derivatives were designed and synthesized as BACE1 inhibitors. The methoxyphenylpyrimidone fragment of B51 was transformed into a methoxyphenylmethylisoxazole/isothiazole moiety to reduce the molecular weight while retaining the ability to fit into the S1' and S2' subpocket of BACE1 as predicted by docking studies. The effects of BACE1 inhibition and the structure-activity relationships were analyzed. Among all 20 designed compounds, 5t exhibited almost 10-fold improved potency (IC50 = 5.33 μM) compared to B51 in the BACE1 inhibition assay. Additionally, it has exhibited rapid binding, slow dissociation kinetics in SPR analysis, suggesting a longer inhibitory effect than B51. All acquired methylisoxazole/isothiazole derivatives were small in size and safe to normal cells, which allow them represent a novel scaffold for BACE1 inhibitor design.

Key words: Alzheimer’s disease, BACE1 inhibitor, Methylisoxazole/isothiazole amides

CLC Number: